Bio App key facts
as of Oct 2026- Operator of a biotechnology company intended to offer a plant-derived genetically modified subunit vaccine for the prevention of swine fever.
- Bio App is valued at approximately $87.3M as of Oct 2026 (last reported valuation).
- It has raised $3.8M; the latest was Later Stage VC in Nov 2025.
- Notable investors include Posco Investment, EcoPro Partners, BNK Venture Capital, CKD Venture Capital, DT & Investment — 9 tracked in total.
- Status: Privately Held (backing).
Bio App's last reported valuation, Jul 2022. Nothing priced has surfaced since.
- ·Watch Bio App: the Monday email on marks, rounds and moves
Bio App funding rounds
No funding rounds for Bio App are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Bio App valuation
Bio App's last reported valuation was $87.3 million in Jul 2022. No priced round, secondary trade or fund mark has surfaced since.
Bio App investors
9 investors are on record for Bio App, including Posco Investment, EcoPro Partners, BNK Venture Capital and CKD Venture Capital.
About Bio App
Operator of a biotechnology company intended to offer a plant-derived genetically modified subunit vaccine for the prevention of swine fever. The company researches and develops plant-based green vaccine products for swine fever and African swine fever, as well as human medicines such as COVID-19, enabling doctors to prescribe biomedicine without any fear of side effects.
- Sector
- Healthcare
- HQ
- Pohang, South Korea
- Founded
- 2011
- Employees
- 36
- Website
- bioapplications.global/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.